Study of Adverse Drug Events in Adults on Oral Anticoagulants Admitted to the Emergency Department

What this Trial Is About

Researchers are studying patients who are admitted to the emergency department while taking oral anticoagulant medications, which include drugs like Acenocoumarol, Apixaban, Dabigatran, Fluindione, Rivaroxaban, and Warfarin. These medications are commonly used to prevent blood clots but are linked to serious side effects such as bleeding and thrombosis, which can lead to hospitalizations and even fatal outcomes. The study aims to better understand the characteristics of these patients, especially those experiencing adverse drug events related to their anticoagulant treatment. This observational study will collect data over 24 months from adult patients admitted to the emergency department who are on oral anticoagulant therapy. The research team will focus on identifying adverse drug events like traumatic and spontaneous hemorrhages, overdoses without symptoms, and new blood clots despite treatment. Researchers will also assess adherence to prescribing guidelines, explore causes of adverse events, and evaluate early health risks and economic impacts related to these complications. Participants will be followed during their emergency department visit, where detailed information about their anticoagulant use and any adverse events will be recorded. The study will analyze these data to describe the groups of patients on different oral anticoagulants and to characterize drug-related adverse events. The project will last a total of 36 months, including one year for data analysis after two years of data collection, aiming to improve understanding of the risks and outcomes for patients on anticoagulant therapy.

Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department